CAMDEN, NJ--Officials at the Institute today announced that the Delaware Valley Personalized Medicine Project has been renamed the Coriell Personalized Medicine Collaborative to better reflect the study's collaborative focus and ramifications for healthcare worldwide as well as to position the project for future growth beyond the Delaware Valley.
Launched in December 2007, the Coriell Personalized Medicine Collaborative is a unique study that seeks to discover presently unknown genes that elevate a person's risk of cancer and other complex diseases, to understand why people often respond differently to treatments, and to explore how the resulting information can best be viewed and utilized by participants and their physicians in a secure, user-friendly, web-based system. Participants will have the opportunity to learn about their risks for medically actionable conditions, including cancer, heart disease, diabetes, high blood pressure and high cholesterol. All that is required from participants is a small saliva sample.
"Interest in our personalized medicine project has extended outside the Delaware Valley region," said Dr. Michael Christman, President and CEO of the Coriell Institute. "We realized that the Coriell Personalized Medicine Collaborative name would emphasize the collaborative nature of the project and highlight the importance of all our partnerships."
